---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-005256"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2022-02-15T23:59:59+00:00"
generated_at: "2026-06-27T08:03:36.480129+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AbCellera-discovered antibody bebtelovimab receives FDA EUA for COVID-19 treatment

## Summary
- Bebtelovimab (LY-CoV1404) authorized for mild-to-moderate COVID-19 in high-risk patients 12+.
- Neutralizes Omicron including BA.2 and all known variants; binds rarely mutated spike region.
- Second AbCellera antibody from Lilly collaboration; dosage 175 mg IV injection.
- U.S. government agreed to buy up to 600,000 doses by March 2022, option for 500,000 more.
- CEO Hansen highlights potency; previous antibody bamlanivimab also received EUA.

## SEC filing metadata
- accession: 0001564590-22-005256
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2022-02-15T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000156459022005256/0001564590-22-005256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000156459022005256/abcl-8k_20220211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-005256
- JSON: https://secwatch.observer/filing/0001564590-22-005256.json
- Plain text: https://secwatch.observer/filing/0001564590-22-005256.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.